Pneumonia and Respiratory Infections · Journal article

Antibiotic resistance in K. pneumoniae: perspectives, challenges, health risks, therapeutic approaches

Frontiers in Microbiology · August 17, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a narrative review synthesizing current knowledge on K. pneumoniae virulence, resistance mechanisms, epidemiology, and emerging therapeutic strategies. It identifies K. pneumoniae as an escalating public health threat with expanding antibiotic resistance and virulence but does not report original trial data or quantify treatment efficacy.

What was studied

Narrative review. Klebsiella pneumoniae strains globally; clinical contexts include hospital-acquired infections (pneumonia, urinary tract infections, bloodstream infections) and community settings.. Global perspective; Asia, Europe, and Middle East mentioned as resistance hotspots.

Key findings

K. pneumoniae has evolved into multiple variants: classical (cKP), hypervirulent (hvKP), multidrug-resistant (MDR), and carbapenem-resistant hypervirulent (CR-hvKP) Resistance mechanisms include intrinsic factors (efflux pumps, porin alterations) and acquired determinants (ESBLs, carbapenemases KPC/NDM/OXA-48, 16S rRNA methyltransferases, mcr genes conferring colistin resistance) Epidemiological hotspots of resistance identified in Asia, Europe, and the Middle East

Safety

No quantitative epidemiological data (prevalence, incidence, mortality rates) provided

Who this may help

Clinicians should recognize K. pneumoniae as a pathogen with rapidly evolving resistance and virulence, with limited therapeutic options in some variants. This review highlights the need for improved diagnostics and novel therapeutic strategies but does not provide evidence to change current treatment algorithms.

Plain-language summary

A narrative review synthesizing existing knowledge on mechanisms, epidemiology, and challenges; raises questions about therapeutic approaches rather than reporting original evidence from a controlled study.

Study design

As stated by the source record.

MethodsNarrative review

SettingGlobal perspective; Asia, Europe, and Middle East mentioned as resistance hotspots

Clinical bottom line

Caveats

No original clinical trial data or treatment efficacy metrics reported
No quantitative epidemiological data (prevalence, incidence, mortality rates) provided
No comparison of therapeutic approaches with efficacy data
Review scope and literature selection methodology not described

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Review article; no original experimental or clinical trial design reported.

Directness

limited

Discusses mechanisms, epidemiology, and therapeutic strategies without reporting clinical outcomes or efficacy data.

Consistency

insufficient

No comparison of conflicting findings or meta-analysis; synthesis of literature not detailed.

Risk of bias

insufficient

Review article; no discussion of selection criteria, quality assessment, or bias appraisal.

Sample adequacy

insufficient

Not applicable to narrative review; no primary data collection or sample size reported.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Klebsiella pneumoniae is an opportunistic Gram-negative pathogen of increasing global concern due to its expanding virulence potential and rapid acquisition of antimicrobial resistance. Traditionally associated with hospital-acquired infections such as pneumonia, urinary tract infections, and bloodstream infections, K. pneumoniae has evolved into a highly diverse species comprising classical (cKP), hypervirulent (hvKP), multidrug-resistant (MDR), and emerging carbapenem-resistant hypervirulent (CR-hvKP) variants. Its pathogenicity is driven by a wide array of virulence factors, including capsular polysaccharides, siderophores, fimbriae, lipopolysaccharides, and multiple secretion systems, all of which facilitate immune evasion, tissue invasion, biofilm formation, and environmental survival. Parallel to this, K. pneumoniae has developed extensive resistance through intrinsic mechanisms, such as efflux pumps and porin alterations, as well as acquired determinants including ESBLs, carbapenemases (KPC, NDM, and OXA-48), 16S rRNA methyltransferases, and plasmid-mediated mcr genes conferring colistin resistance. These combined traits have led to widespread dissemination of MDR and XDR strains, limiting therapeutic options and contributing to significant morbidity, mortality, and healthcare burdens worldwide. Epidemiologically, resistance hotspots have emerged in Asia, Europe, and the Middle East, while hvKP continues to expand beyond its original endemic regions. Diagnostic challenges, therapeutic limitations, and economic pressures further complicate clinical management. This review synthesizes current knowledge on K. pneumoniae virulence mechanisms, resistance evolution, epidemiology, and clinical impact, and highlights emerging therapeutic strategies aimed at overcoming this escalating public health threat.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Bence RaposaShiva Eivazi BagheriGamze AyakdaşDuygu AğagündüzPneumonia and Respiratory InfectionsTülay KandemirFatih Özoğul